Join
Live feed
·
PRReleasevia Quantisnow
ProQR Therapeutics N.V. logo

ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

ByQuantisnow·Wall Street's wire, on your screen.
PRQR· ProQR Therapeutics N.V.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PRQR (ProQR Therapeutics N.V.) and more on Quantisnow.